Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Martin-Broto, J; Hindi, N; Lopez-Pousa, A; Peinado-Serrano, J; Alvarez, R; Alvarez-Gonzalez, A; Italiano, A; Sargos, P; Cruz-Jurado, J; Isern-Verdum, J; Dolado, MC; Rincon-Perez, I; Sanchez-Bustos, P; Gutierrez, A; Romagosa, C; Morosi, C; Grignani, G; Gatti, M; Luna, P; Alastuey, I; Redondo, A; Belinchon, B; Martinez-Serra, J; Sunyach, MP; Coindre, JM; Dei Tos, AP; Romero, J; Gronchi, A; Blay, JY; Moura, DS.

Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas A Nonrandomized Phase 1/2 Clinical Trial

JAMA Oncology. 2020; 6(4): 535-541 Nº de citas: 41 [doi:10.1001/jamaoncol.2019.6584]

Martin, AJM; Ramirez, SP; Moran, LO; Zamorano, MR; Beneitez, MCV; Salcedo, IA; Escobar, IG; Fernandez, JMS.

Pharmacological cancer treatment and venous thromboembolism risk

EUROPEAN HEART JOURNAL SUPPLEMENTS. 2020; 22(C): 2-14 Nº de citas: 17 [doi:10.1093/eurheartj/suaa004]

Becattini, C; Verso, M; Munoz, A; Agnelli, G.

Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients

Haematologica-The Hematology Journal. 2020; 105(3): 838-848 Nº de citas: 28 [doi:10.3324/haematol.2019.221424]

Jimenez, GD; Amo, FH; Arija, JAA; Fernandez, ER; Rios, DS; Garcia, EL; Chomon, GB; Gil, MJC; Rodriguez, JC; Fernandez, CH.

Effect of adjuvant chemotherapy in locally advanced urothelial carcinoma of the bladder treated with cystectomy

Actas Urologicas Espanolas. 2020; 44(2): 94-102 Nº de citas: 5 [doi:10.1016/j.acuro.2019.08.009]

Chau, I; Fakih, M; Garcia-Alfonso, P; Linke, Z; Casado, AR; Marques, EP; Picard, P; Celanovic, M; Cartwright, T.

Safety and Effectiveness of Aflibercept plus Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) for the Treatment of Patients with Metastatic Colorectal Cancer (mCRC) in Current Clinical Practice: OZONE Study

Cancers. 2020; 12(3): Nº de citas: 11 [doi:10.3390/cancers12030657]

Roldan-Romero, JM; Beuselinck, B; Santos, M; Rodriguez-Moreno, JF; Lanillos, J; Calsina, B; Gutierrez, A; Tang, K; Lainez, N; Puente, J; Castellano, D; Esteban, E; Climent, MA; Arranz, JA; Albersen, M; Oudard, S; Couchy, G; Caleiras, E; Montero-Conde, C; Cascon, A; Robledo, M; Rodriguez-Antona, C; Garcia-Donas, J; Pinto, A; Hernando-Polo, S; Grande, E; Domenech, M; Virizuela, JA; Saez, MI; Rodriguez-Lajusticia, L; Duran, I; Gonzalez-Billalabeitia, E; Gallardo, E; del Alba, AG; Bellmunt, J; Mellado, B; Font, A; Alonso-Gordoa, T; Spanish Oncology Genitourinary Grp.

PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma

INTERNATIONAL JOURNAL OF CANCER. 2020; 146(5): 1435-1444 Nº de citas: 24 [doi:10.1002/ijc.32579]

Bendell, JC; Sauri, T; Gracian, AC; Alvarez, R; Lopez-Lopez, C; Garcia-Alfonso, P; Hussein, M; Miron, MLL; Cervantes, A; Montagut, C; Vivas, CS; Bessudo, A; Plezia, P; Moons, V; Andel, J; Bennouna, J; van der Westhuizen, A; Samuel, L; Rossomanno, S; Boetsch, C; Lahr, A; Franjkovic, I; Heil, F; Lechner, K; Krieter, O; Hurwitz, H; McCAVE Study Group.

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

ONCOLOGIST. 2020; 25(3): 451-459 Nº de citas: 38 [doi:10.1634/theoncologist.2019-0291]

Slamon, DJ; Neven, P; Chia, S; Fasching, PA; De Laurentiis, M; Im, SA; Petrakova, K; Bianchi, GV; Esteva, FJ; Martin, M; Nusch, A; Sonke, GS; De la Cruz-Merino, L; Beck, JT; Pivot, X; Sondhi, M; Wang, YB; Chakravartty, A; Rodriguez-Lorenc, K; Taran, T; Jerusalem, G.

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

NEW ENGLAND JOURNAL OF MEDICINE. 2020; 382(6): 514-524 Nº de citas: 638 [doi:10.1056/NEJMoa1911149]

Rugo, HS; Ettl, J; Hurvitz, SA; Goncalves, A; Lee, KH; Fehrenbacher, L; Mina, LA; Diab, S; Woodward, NE; Yerushalmi, R; Goodwin, A; Blum, JL; Martin, M; Quek, RGW; Tudor, IC; Bhattacharyya, H; Gauthier, E; Litton, JK; Eiermann, W.

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy

JNCI Cancer Spectrum. 2020; 4(1): Nº de citas: 25 [doi:10.1093/jncics/pkz085]

Hurvitz, SA; Martin, M; Press, MF; Chan, D; Fernandez-Abad, M; Petru, E; Rostorfer, R; Guarneri, V; Huang, CS; Barriga, S; Wijayawardana, S; Brahmachary, M; Ebert, PJ; Hossain, A; Liu, JG; Abel, A; Aggarwal, A; Jansen, VM; Slamon, DJ.

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2(-) Breast Cancer

CLINICAL CANCER RESEARCH. 2020; 26(3): 566-580 Nº de citas: 191 [doi:10.1158/1078-0432.CCR-19-1425]

Feliu, J; Garcia-Carbonero, R; Capdevila, J; Guasch, I; Alonso-Orduna, V; Lopez, C; Garcia-Alfonso, P; Castanon, C; Sevilla, I; Cerezo, L; Conill, C; Quintana-Angel, B; Sanchez, ME; Ghanem, I; Martin-Richard, M; Lopez-Gomez, M; Leon, A; Caro, M; Fernandez, T; Maurel, J.

VITAL phase 2 study: Upfront 5-fluorouracil, mitomycin-C, panitumumab and radiotherapy treatment in nonmetastatic squamous cell carcinomas of the anal canal (GEMCAD 09-02)

Cancer Medicine. 2020; 9(3): 1008-1016 Nº de citas: 9 [doi:10.1002/cam4.2722]

Martin, AJM; Diaz, EG; Escobar, IG; Montero, RM; Martinez-Marin, V; Olmos, VP; Segura, PP; Verduguez, TQ; Fernandez, MS.

SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019)

Clinical & Translational Oncology. 2020; 22(2): 171-186 Nº de citas: 43 [doi:10.1007/s12094-019-02263-z]

Jerez, Y; Marquez-Rodas, I; Aparicio, I; Alva, M; Mart?n, M; L?pez-Tarruella, S.

Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations

DRUGS. 2020; 80(2): 131-146 Nº de citas: 14 [doi:10.1007/s40265-019-01235-5]

Lazaro, M; Valderrama, BP; Suarez, C; de-Velasco, G; Beato, C; Chirivella, I; Gonzalez-Del-Alba, A; La?nez, N; M?ndez-Vidal, MJ; Arranz, JA.

SEOM clinical guideline for treatment of kidney cancer (2019)

Clinical & Translational Oncology. 2020; 22(2): 256-269 Nº de citas: 20 [doi:10.1007/s12094-019-02285-7]

Lluch A; Barrios CH; Torrecillas L; Ruiz-Borrego M; Bines J; Segalla J; Guerrero-Zotano Á; García-Sáenz JA; Torres R; de la Haba J; García-Martínez E; Gómez HL; Llombart A; Bofill JS; Baena-Cañada JM; Barnadas A; Calvo L; Pérez-Michel L; Ramos M; Fernández I; Rodríguez-Lescure Á; Cárdenas J; Vinholes J; Martínez de Dueñas E; Godes MJ; Seguí MA; Antón A; López-Álvarez P; Moncayo J; Amorim G; Villar E; Reyes S; Sampaio C; Cardemil B; Escudero MJ; Bezares S; Carrasco E; Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group).

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(3): 203-213 Nº de citas: 112 [doi:10.1200/JCO.19.00904]

Gerber, DE; Infante, JR; Gordon, MS; Goldberg, SB; Martin, M; Felip, E; Garcia, MM; Schiller, JH; Spigel, DR; Cordova, J; Westcott, V; Wang, YL; Shames, DS; Choi, Y; Kahn, R; Dere, RC; Samineni, D; Xu, J; Lin, KD; Wood, K; Royer-Joo, S; Lemahieu, V; Schuth, E; Vaze, A; Maslyar, D; Humke, EW; Burris, HA.

Phase Ia Study of Anti-NaPi2b Antibody-Drug Conjugate Lifastuzumab Vedotin DNIB0600A in Patients with Non-Small Cell Lung Cancer and Platinum-Resistant Ovarian Cancer

CLINICAL CANCER RESEARCH. 2020; 26(2): 364-372 Nº de citas: 46 [doi:10.1158/1078-0432.CCR-18-3965]

Marin-Barrera, L; Muñoz-Martin AJ; Rios-Herranz, E; Garcia-Escobar, I; Beato, C; Font, C; Oncala-Sibajas, E; Revuelta-Rodriguez, A; Areses, MC; Rivas-Jimenez, V; Moreno-Santos, MA; Ballaz-Quincoces, A; Lopez-Saez, JB; Gallego, I; Elias-Hernandez, T; Asensio-Cruz, MI; Chasco-Eguilaz, L; Garcia-Gonzalez, G; Estevez-Garcia, P; Otero, R; Lima-Alvarez, J; Jara-Palomares, L.

A Case-Control Analysis of the Impact of Venous Thromboembolic Disease on Quality of Life of Patients with Cancer: Quality of Life in Cancer (Qca) Study

Cancers. 2020; 12(1): Nº de citas: 24 [doi:10.3390/cancers12010075]

Aranda, E; Vieitez, JM; Gomez-Espana, A; Calle, SG; Salud-Salvia, A; Grana, B; Garcia-Alfonso, P; Rivera, F; Quintero-Aldana, GA; Reina-Zoilo, JJ; Gonzalez-Flores, E; Fernandez, MS; Guillen-Ponce, C; Garcia-Carbonero, R; Safont, MJ; Munoa, AL; Garcia-Paredes, B; Lopez, RL; Sastre, J; Diaz-Rubio, E.

FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and >= 3 circulating tumour cells: the randomised phase III VISNu-1 trial

ESMO Open. 2020; 5(6): Nº de citas: 46 [doi:10.1136/esmoopen-2020-000944]